FY2025 EPS Estimates for NeuroPace Raised by HC Wainwright

NeuroPace, Inc. (NASDAQ:NPCE) – Stock analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for NeuroPace in a research report issued on Tuesday, January 27th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.68) for the year, up from their prior estimate of ($0.76). HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for NeuroPace’s Q4 2025 earnings at ($0.10) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.85) EPS.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. The business had revenue of $27.35 million for the quarter, compared to analysts’ expectations of $24.64 million. NeuroPace had a negative net margin of 25.28% and a negative return on equity of 136.60%.

Other equities research analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroPace in a research note on Monday, December 29th. Leerink Partners reiterated an “outperform” rating and set a $19.00 target price on shares of NeuroPace in a research report on Wednesday, November 5th. Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price target on shares of NeuroPace in a research report on Wednesday, November 5th. JPMorgan Chase & Co. lifted their price target on NeuroPace from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Finally, Wells Fargo & Company increased their price objective on shares of NeuroPace from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $18.67.

NeuroPace Trading Down 1.9%

Shares of NeuroPace stock opened at $15.32 on Thursday. NeuroPace has a 12-month low of $7.56 and a 12-month high of $18.98. The company has a current ratio of 4.86, a quick ratio of 3.94 and a debt-to-equity ratio of 3.17. The stock has a market cap of $510.31 million, a PE ratio of -20.16 and a beta of 1.85. The company has a 50-day moving average of $16.26 and a two-hundred day moving average of $12.25.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. lifted its holdings in NeuroPace by 83.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company’s stock valued at $27,000 after purchasing an additional 1,118 shares in the last quarter. Legal & General Group Plc raised its position in shares of NeuroPace by 86.0% in the second quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock valued at $30,000 after buying an additional 1,239 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of NeuroPace during the second quarter valued at approximately $35,000. Quarry LP lifted its stake in shares of NeuroPace by 94.9% during the third quarter. Quarry LP now owns 3,845 shares of the company’s stock valued at $40,000 after buying an additional 1,872 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey boosted its position in NeuroPace by 72.0% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 6,371 shares of the company’s stock worth $71,000 after acquiring an additional 2,668 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.